Thursday, January 27, 2011

Celgene Reports Q4 Results, answers analyst questions

I just posted my summary of the Celgene analyst call and results for Q4 2011.

Celgene just acquired Abraxis and has a large number of clinical trials underway. It looks to me like it could double its revenues again by 2015. Great for a long-term investor, but there is always the risk that drug candidates will fail to be approved.

No comments:

Post a Comment